SW
MTNB icon

Simplicity Wealth’s Matinas BioPharma MTNB Stock Holding History

Simplicity Wealth’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,200
Closed -$9.5K – 948
2024
Q2 		$9.5K Hold
1,200
– – ﹤0.01% 1236
2024
Q1 		$16.3K Buy
+1,200
New +$14.3K ﹤0.01% 1172

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Simplicity Wealth's MTNB Position: Q3 2024 in Review

Simplicity Wealth sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 1,200 shares — an estimated $9.5K sold.

Simplicity Wealth first reported a position in MTNB in Q1 2024 and held it in 2 quarters. The position peaked at $16.3K in Q1 2024. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

  • Simplicity Wealth reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
  • Simplicity Wealth sold 1,200 Matinas BioPharma shares in Q3 2024, an estimated $9.5K.
  • Simplicity Wealth first reported a position in Matinas BioPharma in Q1 2024 and held it in 2 quarters.
  • Simplicity Wealth's Matinas BioPharma position peaked at $16.3K in Q1 2024.
  • 18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Simplicity Wealth's 13F filing for Q3 2024, filed 10 Oct 2024.